FIGO's updated recommendations for misoprostol used alone in gynecology and obstetrics. by Morris, Jessica L et al.
Int J Gynecol Obstet 2017; 1–4	 wileyonlinelibrary.com/journal/ijgo	 	 | 	1© 2017 International Federation of 
Gynecology and Obstetrics
DOI: 10.1002/ijgo.12181
F I G O  S P E C I A L  A R T I C L E
FIGO’s updated recommendations for misoprostol used alone 
in gynecology and obstetrics
Jessica L. Morris1,* | Beverly Winikoff2 | Rasha Dabash2 | Andrew Weeks3 |  
Anibal Faundes4 | Kristina Gemzell-Danielsson5 | Nathalie Kapp6 | Laura Castleman6,7 |  


























by	 indication.	Gestation	 is	 labelled	and	referred	to	as	the	number	of	
weeks	of	gestation	 (<13	weeks,	13–26	weeks,	 and	>26	weeks),	with	





13	 and	 26	weeks,	 and	 for	 termination	 of	 pregnancy	 at	 more	 than	
26	weeks.
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that	complete	expulsion	can	be	safely	achieved	by	continuing	the	regi-
men	up	to	72	hours,	without	compromising	the	woman’s	safety.9
4  | ROUTE OF ADMINISTRATION
Given	 recently	 published	 evidence,2–9	 we	 have	 added	 alternative	
routes	 for	 taking	 misoprostol;	 in	 most	 cases,	 this	 has	 meant	 the	
addition	of	the	buccal	route,	in	which	the	tablets	are	placed	in	the	
cheek	for	30	minutes	after	which	any	remnants	are	swallowed.	This	
route	 has	 a	 similar	 pharmacokinetic	 profile	 to	 the	 vaginal	 route.	
Further	ongoing	studies	are	indicating	this	to	be	a	promising	route	
for	other	 indications	on	 the	 chart,	 but	 these	 indications	have	not	
been	 included	 because	 data	 on	 efficacy	 have	 not	 been	 reported.	
Future	 studies	 will	 continue	 to	 provide	 evidence	 on	 what	 might	
be	 a	 variety	 of	 effective	 regimens	 and	 routes	 of	 administration.	
Although	this	could	result	in	several	available	options	for	providers,	
it	 will	 also	 enable	 women’s	 preferences	 to	 be	 taken	 into	 consid-




include	 the	 rectal	 route.	We	 recommend	 against	 using	 this	 route	
because	the	pharmacokinetic	profile	is	not	associated	with	the	best	
efficacy.
5  | MISOPROSTOL USE IN PREGNANCIES 
WITH PREVIOUS CESAREAN OR 
TRANSMURAL UTERINE SCAR


















who	 have	 had	 a	 previous	 cesarean	 or	 transmural	 uterine	 scar.	
Therefore,	without	evidence	to	support	a	safe	regimen,	we	do	not	
provide	 one,	 other	 than	 to	 recommend	 following	 local	 protocol	 in	
these	cases.
6  | MANAGEMENT OF PREGNANCY 








ity	 of	 one	dose	or	 schedule	 of	misoprostol	 over	 another	 for	 use	 in	
pregnancies	 at	 or	 over	 13	weeks’	 gestation.	 In	 making	 recommen-












any	 benefit	 over	 placebo.22	We	 therefore	 do	 not	 recommend	mis-
oprostol	for	retained	placenta	in	late	pregnancy.
8  | SECONDARY PREVENTION OF 
POSTPARTUM HEMORRHAGE FOR 
COMMUNITY- BASED PROGRAMS
Secondary	prevention	 is	a	community-	based	strategy	 that	has	been	








it	 involves	 medicating	 far	 fewer	 women	 (5%–10%	 vs	 100%),	 thus	
causing	fewer	adverse	effects	and	reducing	costs.
9  | CONCLUSION
The	 FIGO	 Misoprostol-only Recommended Regimens 2017	 chart	
(Fig.	1)	is	the	result	of	extensive	collaboration	among	an	international	
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expert	 group.	 It	 has	 been	 endorsed	 by	 the	 FIGO	 Prevention	 of	
Unsafe	 Abortion	Working	 Group	 and	 the	 FIGO	 Safe	Motherhood	
and	Newborn	Health	Committee,	and	approved	by	the	FIGO	Officers.	







be	 used	 in	 preference	 over	 oxytocin	 for	 postpartum	 hemorrhage,	
or	 instead	 of	 mifepristone	 plus	misoprostol	 for	 pregnancy	 termina-
tion,	 it	 could	be	 the	only	medicine	available	 in	some	circumstances,	
which	 is	why	FIGO	believes	this	 “misoprostol-	only”	chart	 is	needed.	
Misoprostol	must	continue	to	be	highlighted	as	an	essential	medicine	




The	 recent	WHO	guidelines	on	health	worker	 roles	 in	providing	
safe	abortion	care23	outline	a	wide	variety	of	healthcare	providers	who	
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